Vincristine Liposomal

DEA Class; Rx

Common Brand Names; Marqibo

• Antineoplastics, Vinca Alkaloid

Hypersensitivity

Demyelinating conditions including Charcot-Marie-Tooth syndrome

Intrathecal administration

• Blood and lymphatic system disorders (56.6%)
• Infections (39.8%)
• General disorders and administration site condition (37.3%)
• Neuropathy (32.5%)
• Febrile neutropenia (31.3%)
• Respiratory thoracic and mediastinal disorders (20.5%)
• Investigations (24.1%)
• Gastrointestinal disorders (25.3%)
• Neutropenia (18.1%)
• Peripheral sensory and motor neuropathy (16.7%)
• Anemia (16.9%)
• Thrombocytopenia (16.9%)
• Pyrexia (14.5%)
• Fatigue (12%)
• Psychiatric disorders (10.8%)
• Cardiac disorders (10.8%)

For IV use only; other routes may result in fatalities

Death has occurred with intrathecal administration

Do not confuse liposomal injection with vincristine injection due to different dosage recommendations; verify drug name and dose prior to administration

Based on its mechanism of action and findings from animal studies, there are insufficient data on use in pregnant women to evaluate for a drug-associated risk; drug can cause fetal harm when administered to pregnant women

If drug is used during pregnancy, or if patient becomes pregnant while taking drug, patient should be apprised of potential hazard to fetus

There are no data on presence of drug or metabolites in human milk, effects on breastfed child, or on milk production